Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

NCT00129844 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma
Non-Small-Cell Lung Carcinoma
Lung Neoplasms

Interventions

DRUG: Motexafin Gadolinium

Sponsor

Pharmacyclics LLC.